EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Everest Medicines's enterprise value is HK$5,075.7 Mil.
Everest Medicines's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$137.7 Mil. Therefore, Everest Medicines's EV-to-Revenue for today is 36.85.
The historical rank and industry rank for Everest Medicines's EV-to-Revenue or its related term are showing as below:
HKSE:01952'
s EV-to-Revenue Range Over the Past 10 Years
Min: 20.22 Med: 267.62 Max: 485.34
Current: 37.98
During the past 6 years, the highest EV-to-Revenue of Everest Medicines was 485.34. The lowest was 20.22. And the median was 267.62.
HKSE:01952's EV-to-Revenue is ranked worse than 74.23% of 1036
companies
in the Biotechnology industry
Industry Median: 8.17
vs HKSE:01952: 37.98
As of today (2024-05-29), Everest Medicines's stock price is HK$22.10.
Everest Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.43. Therefore, Everest Medicines's PS Ratio for today is 51.76.
Everest Medicines EV-to-Revenue Historical Data
The historical data trend for Everest Medicines's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Everest Medicines's EV-to-Revenue
For the Biotechnology subindustry, Everest Medicines's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Medicines's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Everest Medicines's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Everest Medicines's EV-to-Revenue falls into.
Everest Medicines's current Enterprise Value is HK$5,075.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Everest Medicines's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$137.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Everest Medicines's share price for today is HK$22.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.43.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Everest Medicines EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Everest Medicines's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Everest Medicines (HKSE:01952) Business Description
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01952 has been successfully added to your 